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Background: The purpose of this prospective study is to evaluate if the association of Bethesda
system and a 3-categories Ultrasonography (US) risk stratification system proposed by the
American Association of Clinical Endocrinologists/American College of Endocrinology/Asso-
ciazione Medici Endocrinologi improves the performance of cytology alone in III or IV cate-
gories and if further variables such as US provider (radiologist; endocrinologist, or endocrine
surgeon both coming from a dedicated team) influence the accuracy of the diagnostic.
Methods: 570 consecutive patients with complete clinical records, affected by Bethesda III or
IVnodules, havebeenaddressed to twopublic referral surgical centers ofWesternSicily. Age,
sex, autoimmunity, nodule size, andUS providerwere recorded. Fisher’s exact test was used
for the univariate analysis; Odd’s ratios were calculated for the multivariate analysis.
Results: 248 patients had malignancy at histology, 322 were benign. The mean age was
52 years for the malignancy group and 58 y for the benign group (P < 0.001). At univariate
analysis, autoimmunity was correlated with benign group (P < 0.001), and US risk 2 and 3n was performed by D.L.B. and J.L.; data collection was performed by G.M., G.O., and A.C.;
t draft of the manuscript was written by C.C.; G.S.. G.C. contributed in study conception and
l. All authors commented on previous versions of the manuscript. All authors read and
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204 j o u r n a l o f s u r g i c a l r e s e a r c h  j u n e 2 0 2 1 ( 2 6 2 ) 2 0 3e2 1 1were correlated with malignancy (nearly 10-folds, P < 0.001); In addition, no difference was
found concerning nodule size. At multivariate analysis, US risk 2 and 3 were strong pre-
dictors of malignancy (P < 0.0001) especially if cytology was Bethesda IV; endocrinologist
and surgeon were more accurate in predicting malignancy compared with the radiologist
(P < 0.01).
Conclusions: In the context of indeterminate nodules, the American College of Endocri-
nology/American Association of Clinical Endocrinologists/Associazione Medici Endo-
crinologi US risk stratification system strongly improves the results of Bethesda system
especially when performed from dedicated endocrinologist or endocrine surgeon.
ª 2020 Elsevier Inc. All rights reserved.Background thyroid surgery in Western Sicily: General and EmergencyThyroid ultrasonography is a sensitive and specific examina-
tion in evaluating thyroid nodules; it is the crucial imaging
tool used to identify and classify thyroid lesions. Moreover, it
addresses suspicious nodules for fine-needle aspiration bi-
opsy (FNAB) for obtaining tissue samples and is useful to
confirm or rule out malignancies.1,2 Because its sensitivity
could increase the number of unnecessary FNABs and diag-
nostic surgeries performed for “low-risk” lesions, statements
for US risk and stratification have been suggested in several
studies.3,4
Currently, the screening of lesions referred to surgery is
performed as per the cytology results once US preselection
has been performed earlier. Several scientific societies or in-
dividual research groups have proposed different systems for
the assessment of US risk stratification of thyroid nodules.5-7
A simple scoring system for US reporting has been proposed
by the American Association of Clinical Endocrinologists
(AACE), the American College of Endocrinology (ACE), and the
(Italian) Associazione Medici Endocrinologi (AME). They pro-
posed a new US rating system for the risk of malignancy for
thyroid nodules, which is a three-category system that
appeared easy to apply in practice.8 Concerning cytology, the
Bethesda system for reporting thyroid cytopathology had
widespread diffusion and represented a step forward in sys-
tematizing the interpretation of cytology.9 At the same time, it
is the landmark for benign (Bethesda II), suspected (Bethesda
V), or confirmed (Bethesda VI) malignant nature of a thyroid
nodule. Both US and cytopathology separately have excellent
diagnostic accuracy; however, no consensus has been reached
to date in the treatment of undetermined (Bethesda III and IV)
lesions.
This study aimed to verify the hypothesis that US, per-
formed as per the ACE/AACE/AME US risk stratification sys-
tem, is capable of increasing the diagnostic performance of
cytology in Bethesda III and IV cytology categories assuming
the same frequency of malignancy in both classes. Moreover,
we evaluated whether providers performing US could influ-
ence the accuracy of the diagnosis, especially in terms of
correct indication for surgery.Methods
This institutional prospective study was performed in two
public high-volume centers (>100 thyroidectomies/year) forSurgery and General and Oncological Surgery both belong to
the Department of Surgical, Oncological, and Oral Sciences of
the University of Palermo. Together with the endocrinologists
of the Endocrinology andMetabolic Diseases unit of Policlinico
"P. Giaccone," University of Palermo, and two expert endo-
crinologists of Palermo district ("Azienda Ospedaliera Ospe-
dali Riuniti Villa Sofia-Cervello" and "Ospedale Civico di
Partinico"), two high-volume surgeons at high-volume centers
who work on a multidisciplinary, dedicated team and share
protocols, and guidelines and consensus meetings for the
management of clinical cases participated in the study.
The study enrolled consecutive patients who underwent
thyroidectomy (thyroid lobectomy or total thyroidectomy)
from January 2012 to June 2019. Patients referred at one of the
high-volume centers hadUS performed in one of the following
settings: external radiologist/ultrasonographer (provider 1),
one among expert endocrinologists on the dedicated team
(provider 2), and one between endocrine surgeons of the
dedicated team (provider 3). US was always performed by
echographs endowed with a high-frequency (7,5-12 mHz)
probe. Because the ACE/AACE/AME US risk score was used at
our institution beginning on June 2016, and it is not diffusely
applied to date, reports of external radiologists, or those per-
formed before June 2016, were led back to the ACE/AACE/AME
score system if possible. In both these circumstances, the risk
score was assigned by the two thyroid surgeons after they had
discussed the reinterpretation of the ultrasound reports and,
when available, the archived images captured by the original
provider. Patients with a lack of data in which this report’s
translation was impossible or unclear were excluded from the
study. All patients were recruited after an outpatient evalua-
tion in one of the two surgery units or referral for surgery after
endocrinology evaluation performed at our institution or
elsewhere.
Criteria for surgery in the group of undetermined/suspi-
cious lesions were Bethesda IV (all) or growing Bethesda III
lesions, suspicious US findings (irregular/speculated margins,
markedly hypoechoic nodules, intralesional irregular vascu-
larization, microcalcifications, "taller than wide" shape, etc.)
nodules> 4 cm inmajor diameter especially in the presence of
compressive symptoms, and cosmetic and/or psychological
concerns, including the patient’s intolerance to long-term
follow-up. These criteria were consistent during the study
period.
Patients suffering from any thyroid nodular disease (single
nodule, multinodular goiter) with complete clinical records
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laboratory tests, operative report, and definitive histology)
were included in the study.
We excluded US reports not in agreement with the AACE/
ACE/AME standards, the absence of cytopathologic reports, or
incomplete descriptions in accordance with the Bethesda
system. Moreover, we excluded benign thyroid diseases
(Grave’s disease) and malignancies (medullary thyroid carci-
nomas) because their diagnoses are strongly connected with
specific laboratory tests and all malignancies other than
differentiated of follicular origin. We also excluded patients
with family history of thyroid cancer, personal history of neck
irradiation, or previous malignancy. Finally, we excluded pa-
tients with diagnosed (clinical, US, or intraoperative) gross
extrathyroidal extension disease, including central and/or
lateral metastases because we did not evaluate this specific
topic.
Figure 1 summarizes in a flow chart the enrollment process
highlighting the number of patients excluded and the reason
for their exclusion.
Patients enrolled in this study had complete clinical re-
cords, including US and cytology. US risk stratification was
classified into 3 categories (1 ¼ low risk; 2 ¼ intermediate risk;
3 ¼ high risk) as per ACE/AACE/AME criteria (Table 1).
An endocrinologist or endocrine surgeon performed fine-
needle aspiration, and slides obtained were examined by a
dedicated pathologist at a university hospital. Cytology was
reported as per Bethesda criteria. Only patients affected by
nodules classified as Bethesda III and IV (thyroid nodules that
showed atypia of uncertain significance or follicular lesion of
undetermined significance and follicular neoplasm or suspi-
cious for follicular neoplasms) were included.
The US provider (radiologist, endocrinologist, and endo-
crine surgeon) was also recorded. Because all nodules were
evaluated in a team manner before they were referred to
surgery, US performed by a radiologist was always repeated,
but only the prereferral report was recorded for this study.
Age, sex, autoimmunity (assessed as per autoantibodies
anti-TPO and anti-TG serum levels and confirmed at histo-
logical report), and nodule size (measured on US but defini-
tively established as per histologic report) were also included
in the recorded variables to evaluate their possible influence
on the results. The "T" category was established as per the
TNM staging system, AJCC/UICC, seventh edition, in which T1
size was subdivided into T1a (10 mm in diameter) and T1b
(11-20 mm).10,11 All data were related to definitive results of
pathology, identifying two groups: benign (B) and malignant
(M) at definitive histology.
The nodule assessedwith FNAB andultrasoundwas indeed
confirmed to be the nodule thatwas considered for the present
study as histologically benign or malignant. As per prevailing
literature trends,12 the three non-invasive follicular thyroid
neoplasms with papillary- like nuclear features diagnosed
after thyroidectomy (one reported as Bethesda III in preoper-
ative workup, two Bethesda IV) were classified as benign.
The present study was performed as per the declaration of
Helsinki (1964) and its amendments, informed consent was
obtained and the Ethics Committee of Azienda Ospedalier-
odUniversitaria Policlinico “P. Giaccone”dPalermo approved
the study.Statistical analysis
Datawere included as discrete in an Excel sheet. Fisher’s exact
test was used for univariate analysis, and odds ratios were
calculated in a logistic regression model for multivariate
analysis. IDE RStudio software (version 3.4.1 of 2017-06-30)
was used for univariate and multivariate analysis.Results
A total of 570 patients (526 women, 92%; 44 men, 8%) matched
the recruitment criteria. Themean agewas 56 y (range: 20-86).
In 248 patients (43.5%), the definitive diagnosis was ma-
lignant nodule (M group) at histologic report, 322 patients
(56.5%) had benign nodules (B group). The mean age was
significantly different between the two groups: 52 years for the
M group and 58 for the B group (P < 0.001). The distribution of
sex in the two groups was homogeneous (P ¼ 0.16). The uni-
variate analysis investigated the relation between each vari-
able and the definitive result of histology (Table 2). As
expected, the relation of Bethesda category and histology had
a P-value in the range of nonsignificance. In this analysis, the
chi-square test measured the degree of relationship of each
Bethesda value with histology, evaluated as a dichotomous
variable (benign/malign). Therefore, both undetermined cat-
egories have an increased risk of malignancy although their
distributions are statistically different.
The logistic regression showed that, at least in the series of
patients examined, more advanced age and autoimmunity
seem to be protective toward malignancy (OR ¼ 0.98 and 0.56,
respectively). In particular, the variable "age" was categorized
by dividing it into 3 ranges: <45 y, 45-60 y, and > 60 y. This
solution was preferred because it allows to identify for which
age group the risk of malignancy was protective. The refer-
ence group of patients <45 y had an OR ¼ 1 (not significant);
therefore, the group of patients ranging 45-60 y in comparison
with <45 y had an OR ¼ 0.71, statistically not significant; the
patients >60 y compared with the <45 y old showed an
OR ¼ 0.48 (P < 0.01). It means that age>60 y is protective
against thyroid cancer.
Bethesda category IV is correlatedwithmalignancy 1.5-fold
compared with category III. In this model, the Bethesda cate-
gory is considered as a qualitative variable. In this case, the
significance should be interpreted as the excess risk of ma-
lignancy of Bethesda IV compared with Bethesda III. The
correlation of advanced US risk category (2 and 3) with the M
group was strong, and both categories were capable of
revealing malignancy nearly 10-fold compared with US risk
category 1.
Figure 2 shows the relationship between sensitivity and
specificity of ACE/AACE/AME risk scale by means of a ROC
curve. In our study, it has shown a moderate accuracy.
Gender and nodule size did not influence the risk of ma-
lignancy. On the contrary, the variable "autoimmunity," if
present, seemed to be a protective factor against malignancy.
At multivariate analysis, US risks 2 and 3 were strong inde-
pendent predictors ofmalignancy (P< 0.0001), especially if the
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Fig. 1 e Patient recruitment process. Starting from the total number of patients identified during outpatient endocrine
surgery visit of the units involved in the study, a description is given of how many patients were excluded, at what stage of
the process and for what reasons. (Color version of figure is available online.)
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Table 1 e ACE/AACE/AME US risk scores.
Class 1: Low-risk thyroid lesion (expected risk of malignancy: about 1%)
- Mostly cystic (>50%) nodules with reverberating artifacts that are not associated with suspicious US signs;
- Isoechoic spongiform nodules confluent or with regular halo
Class 2: Intermediate risk thyroid lesion (expected risk of malignancy: 5-15%)
- Slightly hypoechoic nodules (compared with surrounding thyroid tissue) and isoechoic nodules with ovoid to round shape and smooth or ill-
defined margins
- Either intranodular vascularization, elevated stiffness at elastography, macrocalcifications or continuous rim calcifications, or hypoechoic
spots of uncertain significance may be present
Class 3: High-risk thyroid lesion* (expected risk of malignancy: 50-90%)
- Marked hypoechogenicity (compared with prethyroid muscles)
- Spiculated or microlobulated margins
- Microcalcifications
- Taller-than-wide shape
- Evidence of extrathyroidal growth or pathologic adenopathy
*Nodules with at least one of the following suspicious features.
From: Gharib H, and coll. See reference.8
Table 2 e Demographics and univariate analysis.
Variable Benign Malignant Total P-value
Mean age 58 52 <0,0001
Gender
F 302 224 526 0.1679
M 20 24 44
Total 322 248 570
Autoimmunity
No 144 172 316 <0.0001
Yes 178 76 254
Total 322 248 570
Size
T1a 61 54 115 0.8365
T1b 208 158 366
T2 50 34 84
T3 3 2 5
Total 322 248 570
US risk
1 152 16 168 <0.0001
2 106 160 266
3 64 72 136
Total 322 248 570
Bethesda
3 137 95 232 0.3495
4 185 153 338
Total 322 248 570
Provider
1 193 84 277 <0.0001
2 35 48 83
3 94 116 210
Total 322 248 570
Univariate analysis: Age showed a significant difference in the two groups (malignancy group was younger); malignancy was more frequent in
patients without autoimmunity; US risk 2 and 3 and in patients addressed to surgery from endocrinologist (provider 2) and surgeon (provider 3);
malignancy was not significantly different in Bethesda III versus IV if this variable was analyzed in this univariate model; nodule size was not a
predictor of malignancy.
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Fig. 2 e ROC curve representing the relationship between
the sensitivity and specificity of the ACE/AACE/AME US
risk score used in this study. Below are the criteria for
evaluating the ability of the scale to detect malignancies.
Sensitivity [ 0.94 CI 95% (0.90-0.96); Specificity [ 0.47 CI
95% (0.42-0.53); c-index AUC [ 0.71 CI 95% (0.66-0.75).
Based on this result, the ACE/AACE/AME US risk score is
moderately accurate. (Color version of figure is available
online.)
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nancy (P < 0.01). Finally, autoimmunity confirmed to be pro-
tective as well as age >60 years against malignancy (Table 3).
Table 4 shows a cross tabulation of US risk by provider,
Bethesda cytology category, and distribution of malignant
versus benign nodules. Out of a total of 47 patients in US risk
class 1 and Bethesda III category, 85% confirmed histologically
their benign nature, with limited variation based on the pro-
vider that reported US. It can also be observed that provider 1
reports a lower percentage of malignancies than benignTable 3 e Multivariate analysis.
Variable OR Inferior limit 95
Age (45-60] 0.71 0.43
Age (>60] 0.48 0.28
Male 1.14 0.57
Autoimmunity 0.52 0.34
Bethesda IV 2.53 1.67
US risk 2 9.81 5.52
US risk 3 9.94 5.32
Provider 2 2.74 1.47
Provider 3 2.26 1.42
T1b size 0.41 0.23
T2 size 0.49 0.23
T3 size 1.98 0.19
In this logistic regression model, Bethesda IV (versus III) is a predictor o
working in the dedicated team (endocrinologist or surgeon versus externalesions in US risk classes 2 and especially 3. Conversely, in
these US risk classes, providers 2 and 3 have higher rates of
malignancy than benign nodules.Discussion
Ultrasound criteria have long oriented thyroid nodules toward
surgery or follow-up. The introduction of score systems
dedicated to thyroid nodules has allowed a more precise se-
lection between lesions for simple follow-up and nodules
requiring FNAB. Only on the basis of the latter investigation,
thyroid nodules could be selected for surgery. This research
aimed to find the best method and the best provider for
reporting thyroid US from the perspective of selecting thyroid
nodules suspected ofmalignancy. For selecting these nodules,
high accuracy is needed. At the same time, unnecessary di-
agnostics for lesions of little clinical significance might be
avoided. Because thyroid nodules are common even in
asymptomatic populations, we must consider that cytology
should be performed only in nodules considered suspicious on
US with the aim of preventing overdiagnosis and over-
treatment and reducing costs.13-15 Several scientific societies
have published different US risk scores that have shown the
capability to accurately identify benign and malignant nod-
ules.16-20 A recent systematic review and meta-analysis21
showed that the Thyroid Imaging, Reporting and Data Sys-
tem proposed by the American College of Radiology (ACR TI-
RADS) seems to be the most performant US score system
compared with AACE/ACE/AME, ATA, EU-TIRADS, and K-
TIRADS. The ACR TI-RADS score system evaluates five cate-
gories of US features: composition, echogenicity, shape,
margin, and echogenic foci. For each feature, 0-3 points are
assigned.22 This meta-analysis emphasizes that the sensi-
tivity and positive and negative values of ACR TI-RADS are not
excellent and a high number of studies evaluated this system.
The AACE/ACE/AME score system was used only in a few
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Provider 1 Provider 2 Provider 3
Benign Malignant Benign Malignant Benign Malignant
*B3 *B4 *B3 *B4 *B3 *B4 *B3 *B4 *B3 *B4 *B3 *B4
1 15 (83%) 86 (96%) 3 (17%) 4 (4%) 9 (100%) 9 (82%) 0 (0%) 2 (18%) 16 (80%) 17 (85%) 4 (20%) 3 (15%)
2 22 (59%) 27 (53%) 15 (41%) 24 (47%) 11 (31%) 3 (18%) 24 (69%) 14 (82%) 32 (47%) 11 (19%) 36 (53%) 47 (81%)
3 19 (73%) 24 (44%) 7 (27%) 31 (56%) 0 (0%) 3 (33%) 2 (100%) 6 (66%) 13 (76%) 5 (18%) 4 (24%) 22 (82%)
*B3-B4¼ Bethesda 3-Bethesda 4. The percentages reported in each box refer to the total number of patients belonging to each Bethesda category
in each US risk class for each provider.
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consuming than ACR TI-RADS. Sensitivity, specificity, and
negative predictive value are performant comparedwith other
risk assessment scales taken into consideration in this re-
view.21 Another review that compares different risk assess-
ment systems shows that the prevalence of malignancy in
high-risk categories is higher in the ACE/AACE/AME system
than in the ATA, K-TIRADS, EU-TIRADS, ACR-TIRADS, and
BTA systems. At the same time, its prevalence is very low (1%)
in the low-risk category.23 The ACE/AACE/AME US reporting
system met the criteria of the reporting system proposed by
Su et al. (2014), which was concerned with easy routine in-
formation workflow, optimization and automation of
communication, standardization of documentation, reliability
of collected data for comparison, and clinical research.24
Concerning the US provider, the importance of surgeon-
performed thyroid ultrasonography is reported by several
studies who reported its effectiveness in characterizing sus-
pected nodules aswell asmalignant lymphnodes.25-27 A study
by Mohanapriya28 showed an improvement in the sensitivity
of surgeons compared with radiology-reported US from
86.05% to 98.53%. The negative predictive value increased
from 83.8% to 98%. Moreover, it is argued that surgeons per-
forming US would be more advantageous, such as for the
detection and evaluation of surgery contemporaneous para-
thyroid diseases29 or suspicious nonrecurrent inferior laryn-
geal nerve.30
Our study showed the significant importance of evaluating
thyroid nodules, not only taking into consideration the results
of cytology but also integrating US reports in the overall
judgment of lesions explored. In fact, US risk 2 and 3 classes
increased the risk of cancer of undetermined (Bethesda III and
IV) nodules nearly 10-fold. On the contrary, out of a total of 47
Bethesda III nodules classified in US risk class 1, only 7 (less
than 15%) were malignant. In our opinion, therefore, as sup-
ported by these data, in this last context, a simple follow-up is
enough. The other side of the coin is that US "low-risk" nod-
ules were less than 30%, so over two-thirds of the sample is
considered quite suspicious in accordance with our method
because the difference between US risk 2 and 3 was slightly in
favor of US risk 3 but not well defined. Notwithstanding, one
undetermined nodule out of three is "low risk." Then, a simple
follow-up is needed, especially for Bethesda III nodules.
Furthermore, the present study clarified the difference
among reports coming from different providers. Endocrinol-
ogists or endocrine surgeons on the team responsible forpatient management performed better in diagnosing thyroid
cancer than radiologists. The role of surgeons (and/or endo-
crinologists) who performed US has recently been empha-
sized,31 and advantages were found in predicting the
benignity of nodules32 as well as detecting malignancies.33
Some studies affirm that imaging performed by radiolo-
gists appears inadequate or incomplete.34 This should be due
to the experience of a dedicated sonographer that follows a
standardization of reports and could obtain continuous feed-
back from clinical to ultrasound findings. On the other hand,
the variations in ultrasound assessment of thyroid lesions
have been demonstrated from an interobserver and intra-
observer perspective.35,36
Although the available literature emphasizes the role of
surgeon-performed US, our study showed that both surgeons
and endocrinologists are able to improve the performance of
US, provided that it is evaluated in the context of a dedicated
team. Thus, we could suppose that additional clinical infor-
mation available to dedicated teams appears crucial for
adequate US reports.
A setting capable of overcoming the lack of clinical
knowledge should be a dedicated radiologist integrated into
the multidisciplinary team, but it is not standardized.37
The optimal scenario for the management of thyroid
nodules as well as other neck endocrine diseases appears to
be a multidisciplinary setting in which essential elements
deemed to be important in each specialty of the team are well
defined.24
The two main questions asked in the present study had
clear answers. The ACE/AACE/AME reporting system
appeared adequate in the characterization of thyroid nodules,
and as deduced from the literature data, no substantial
weakness was described.8,16-22 In fact, both univariate and
multivariate analyses showed that US risk 2 and 3 were
strongly correlated with malignancy.
Concerning which provider should perform US of thyroid
nodules referred for surgery, a member of the dedicated team
(endocrinologist and endocrine surgeon) was much better at
predicting malignancy. It do not seem related to specific
points of US reporting, such as capsular irregularity, micro-
calcifications versus colloid crystals but rather to the overall
“sense” of the entire image although this specific issue was
not specifically evaluated.
The present study included only patients already referred
to surgery, therefore with histologic confirmation. It excludes
that some patients enrolled can hide a malignancy. This
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missing data, because a large number of patients are excluded
before recruitment to a dedicated team; at the same time, our
hospital is a referral center for thyroid surgery, so it can lead to
a selection bias once again because previous US, performed in
a community-based context, may have excluded some "low-
risk" nodules. Probably this strongly affects the non-
significance of the difference between the Bethesda III and IV
categories in univariate analysis in their respective associa-
tion withmalignancy. In our practice, all Bethesda IV nodules,
compared with 70% of Bethesda III nodules, have been taken
into account for the surgery. This could lead to an additional
selection bias which in turn could also explain, at least in part,
why the risk of malignancy in our patients tends to be very
similar in the ultrasound risk categories 2 and 3. In addition, it
could be assumed that patients in the Bethesda III cytopa-
thologic category, not all of whom have undergone surgery,
were preselected as per some risk factors generally accepted
by the scientific community (size, age of the patient, and in-
crease in nodule volume) among which the ultrasound risk
score may have played a predominant role. It is evident that
among these nodules only 47 had a low risk score compared
with 182 intermediate or high-risk score.
More weaknesses of the present study might be pointed
out: the scarce number of nodules of greater size (>4 cm)
included, the heterogeneity of echographs and echographers,
the fact that endocrinologists and surgeons were not blinded
to the results of the radiology performed ultrasound and
report.
Conversely, the prospective nature of the study, the rela-
tively large number of patients enrolled, belonging to a well-
defined type (undetermined nodules), and the unequivocal
characterization of outcomes (benign/malignant) due just to
its biopsy are relevant strengths.
The fact that the nodules addressed to surgery as "suspect"
by providers 2 and 3 was in a much higher percentage ma-
lignant rather than benign (see Table 2), despite being
burdened by the bias previously discussed supports the hy-
pothesis that the US investigations carried out by these op-
erators are much more performant in the detection of
malignant lesions. The results of cross tabulation of US risk by
provider, Bethesda cytology category and distribution of ma-
lignant versus benign nodules (Table 4) confirm that the ul-
trasound reports made by providers belonging to the
dedicated team are much more reliable than the former.
Moreover, in addition to the improved diagnostic perfor-
mance of multidisciplinary team-based management of thy-
roid nodules from a surgical perspective,38 patient
satisfaction, and cost savings should be taken into consider-
ation due to the reduced number of visits.39
The present study investigated the relationship between
the pretest probability of malignancy (relatively high in
Bethesda III and higher in Bethesda IV cytology) and the per-
formance of a prognostic test (ultrasound stratification).
The results of the study may not appear to be in line with
those of the individual risk categories, both in terms of diag-
nostic cytopathology and US.8,9 In this regard, it should be
underlined once again that this is a study conducted on pa-
tients already directed to surgery, so it is to be expected a
relatively higher number of malignancies, which, however,are concentrated in the more advanced risk classes (Bethesda
IV versus III, US risk score 2 and 3 versus 1). This does not affect
the validity of the respective score systems (Bethesda, ACE/
AACE/AME) in which the risk of malignancy is assessed on
studies conducted in patients before surgery was performed.
The novelty of these findings lies in the possibility of
selecting in the most precise way possible and with simple
and routine diagnostic tests the nodules to be addressed to
surgery from those to be subjected to observation.
In conclusion, US performed within a dedicated team and
reported with a simple, reliable, and efficacious scoring sys-
tem achieves optimal results in terms of detecting malig-
nancies, avoiding unnecessary procedures or restricting
surgical aggressiveness.
We can affirm that in the context of indeterminate nodules
(Bethesda III and IV), the ACE/AACE/AME US risk stratification
system strongly improved the results of cytology alone. We
are convinced that this reporting system assures the
communication of minimum essential information among
the members of the team to avoid underestimating malig-
nancies or overrating benign nodules, although a comparison
ACE/AACE/AMEUS risk scores with TI-RADS scores (assuming
this as the reference score system) not performed in the pre-
sent study, is needed to confirm the value and reliability of the
first one.
From this point of view, a surgeon-performed thyroid US
can lead to several advantages over those shown within the
limits of the present study, such as a detailed overview of neck
anatomy and a meticulous report of neck lymph nodes.
US can be repeated many times, even exchanging sensa-
tions and suggestions between surgeons and endocrinologists
in real time, increasing the performance of US once again. It is
a tool that cannot be given up in the diagnosis and staging of
thyroid nodules, and we are resolutely convinced of its value.Disclosure
The authors report no proprietary or commercial interest in
any product mentioned or concept discussed in this article.r e f e r e n c e s
1. Ianni F, Campanella P, Rota CA, et al. A meta-analysis-derived
proposal for a clinical, ultrasonographic, and cytological
scoring system to evaluate thyroid nodules:
the ‘‘CUT’’ score. Endocrine. 2016;52:313e321.
2. Ha EJ, Baek JH, Na DG. Risk stratification of thyroid nodules on
ultrasonography: current status and perspectives. Thyroid.
2017. https://doi.org/10.1089/thy.2016.0654.
3. Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R,
Leenhardt L. European thyroid association guidelines for
ultrasound malignancy risk stratification of thyroid nodules
in adults: the EU-TIRADS. Eur.Thyr J. 2017;6:225e237.
4. Brito JP, Gionfriddo MR, Al Nofal A, et al. The accuracy of
thyroid nodule ultrasound to predict thyroid cancer:
systematic review and meta-analysis. J Clin Endocrinol Metab.
2014;99:1253e1263.
s c e r r i n o e t a l  d i a gn o s t i c p e r f o rm an c e f o r t h y r o i d un d e t e rm i n e d n odu l e s 2115. Park JY, Lee HJ, Jang HW, et al. A proposal for a thyroid
imaging reporting and data system for ultrasound features of
thyroid carcinoma. Thyroid. 2009;19:1257e1264.
6. Shin JH, Baek JH, Chung J, et al. Ultrasonography diagnosis
and imaging-based management of thyroid nodules: revised
Korean society of thyroid radiology consensus statement and
recommendations. Korean J Radiol. 2016;17:370e395.
7. Hong MJ, Na DG, Baek JH, Sung JY, Kim JH. Cytology-
ultrasonography risk-stratification scoring system based on
fine-needle aspiration cytology and the Korean-thyroid
imaging reporting and data system. Thyroid. 2017;27:953e959.
8. Gharib H, Papini E, Garber JR, et al. American Association of
Clinical Endocrinologists, American College of Endocrinology,
and Associazione Medici Endocrinologi Medical guidelines for
clinical practice for the diagnosis and management OF
thyroid nodules-2016 update. Endocr Pract. 2016;22:622e639.
AACE/ACE/AME task force on thyroid nodules.
9. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid
cytopathology. Thyroid. 2009;19:1159e1165.
10. Baek HJ, Kim DW, Ryu JH. Association between TNM staging
system and histopathological features in patients with
papillary thyroid carcinoma. Endocrine. 2015;48:589e594.
11. Chereau N, Trésallet C, Noullet S, et al. Does the T1
subdivision correlate with the risk of recurrence of papillary
thyroid cancer? Langenbecks Arch Surg. 2016;401:223e230.
12. Lindeman BM, Nehs MA, Angell TE, et al. Effect of
noninvasive follicular thyroid neoplasm with papillary-like
nuclear features (NIFTP) on malignancy rates in thyroid
nodules: how to counsel patients on extent of surgery. Ann
Surg Oncol. 2019;26:93e97.
13. Haugen BR, Alexander EK, Bible KC, et al. 2015 American
thyroid association management guidelines for adult patients
with thyroid nodules and differentiated thyroid cancer: the
American thyroid association guidelines task force on thyroid
nodules and differentiated thyroid cancer. Thyroid.
2016;26:1e133.
14. Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very
high prevalence of thyroid nodules detected by high
frequency (13 MHz) ultrasound examination. Eur J Clin Invest.
2009;39:699e706.
15. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal
Maso L. Worldwide thyroid-cancer epidemic? The increasing
Impact of overdiagnosis. N Engl J Med. 2016;375:614e617.
16. Perros P, Colley S, Boelaert K, et al. British Thyroid
Association Guidelines for the management of thyroid
cancer. Clin Endocrinol (Oxford). 2014;81(Suppl 1):1e122.
17. Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting
system for thyroid nodules stratifying cancer risk for clinical
management. J Clin Endocrinol Metab. 2009;94:1748e1751.
18. Ha EJ, Moon WJ, Na DG, et al. A multicenter prospective
validation study for the Korean thyroid imaging reporting and
data system in patients with thyroid nodules. Korean J Radiol.
2016;17:811e821.
19. Lee YH, Kim DW, In HS, et al. Differentiation between benign
and malignant solid using the ATA and ACR-TIRADS
sonographic classifications as adjunctive predictors of
malignancy for indeterminate thyroid nodules. Endocr Pract.
2011;25:908e917.
20. Hamadi S, Herbst R, Oyekunle T, Jiang XS, Strickland K,
Sanzi R, Sosa JA. Using the ATA and ACR-TIRADS sonographic
classifications as adjunctive predictors of malignancy for
indeterminate thyroid nodules. Endocr Pract.
2019;25(9):908e917.
21. Castellana M, Castellana C, Treglia G, et al. Performance of
five ultrasound risk stratification systems in selecting thyroidnodules for FNA. A META-ANALYSIS. J Clin Endocrinol Metab
2019. https://doi.org/10.1210/clinem/dgz170.
22. Tessler FN, Middleton WD, Grant EG. Thyroid imaging
reporting and data system (TI-RADS): a User’s Guide.
Radiology. 2018;287:29e37.
23. Ospina NS, Ariza NMI, Castro MR. Thyroid nodules: diagnostic
evaluation based on thyroid cancer risk assessment. BMJ.
2020;368:l6670. https://doi.org/10.1136/bmj.16670.
24. Su HK, Dos Reis LL, Lupo MA, et al. Striving toward
standardization of reporting of ultrasound features of thyroid
nodules and lymph nodes: a multidisciplinary consensus
statement. Thyroid. 2014;24:1341e1349.
25. Hamer PW, Aspinall SR, Malycha PL. Clinician-performed
ultrasound in assessing potentially malignant thyroid
nodules. ANZ J Surg. 2014;84:376e379.
26. Monteiro R, Han A, Etiwy M, et al. Importance of surgeon-
performed ultrasound in the preoperative nodal assessment
of patients with potential thyroid malignancy. Surgery.
2018;163:112e117.
27. Cohen O, Lahav Y, Halperin D, Yehuda M. Surgeon-performed
ultrasonographic evaluation and predication for large thyroid
nodules-A case-control study. Surgery. 2019;166:1148e1153.
28. Mohanapriya G, Chandrasekaran M. Is a surgeon-performed
ultrasound good enough in diagnosing thyroid malignancy?
Indian J Endocr Metab. 2018;22:181e184.
29. Sloan DA, Davenport DL, Eldridge RJ, Lee CY. Surgeon-driven
thyroid Interrogation of patients presenting with primary
hyperparathyroidism. J Am Coll Surg. 2014;218:674e683.
30. CittonM,Viel G, IacoboneM.Neckultrasonography for detection
of non-recurrent laryngeal nerve. Gland Surg. 2016;5:583e590.
31. Méndez W, Rodgers SE, Lew JI, Montano R, Solorzano CC. Role
of surgeon-performed ultrasound in predicting malignancy in
patients with indeterminate thyroid nodules. Ann Surg Oncol.
2008;15:2487e2492.
32. Goldfarb M, Gondek S, Solorzano C, Lew JI. Surgeon-
performed ultrasound can predict benignity in thyroid
nodules. Surgery. 2011;150:436e441.
33. Jabiev AA, Ikeda MH, Reis IM, Solorzano CC, Lew JI. Surgeon-
performed ultrasound can predict differentiated thyroid
cancer in patients with solitary thyroid nodules. Ann Surg
Oncol. 2009;16:3140e3145.
34. Kumbhar SS, O’Malley RG, Robinson TF, et al. Why thyroid
surgeons are frustrated with radiologists: lessons learned
from pre- and postoperative US. Radiographics RSNA.
2016;36:2141e2153.
35. Choi SH1, Kim EK, Kwak JY, Kim MJ, Son EJ. Interobserver and
intraobserver variations in ultrasound assessment of thyroid
nodules. Thyroid. 2010;20:167e172.
36. Oltmann SC, Schneider DF, Chen H, Sippel RF. All thyroid
ultrasound evaluations are not equal: sonographers
specialized in thyroid cancer correctly label clinical N0
disease in well differentiated thyroid cancer. Ann Surg Oncol.
2015;22:422e428.
37. Carneiro-Pla D, Amin S. Comparison between
preconsultation ultra- sonography and office surgeon-
performed ultrasound in patients with thyroid cancer. World J
Surg. 2014;38:622e627.
38. Hoang JK, Sosa JA, Nguyen XV, Galvin PL, Oldan JD. Imaging
thyroid disease: updates, imaging approach, and
management pearls. Radiol Clin North Am. 2015;53:145e161.
39. Mazzaglia PJ. Surgeon-Performed Ultrasound in patients
referred for thyroid disease improves patient care by
minimizing performance of unnecessary procedures and
optimizing surgical treatment. World J Surg.
2010;34:1164e1170.
